1. Inicio
  2. Proyectos y Estudios
  3. ESTUDIO MULTNACIONAL, MULTICENTRICO, RANDOMIZADO, DOBLE CIEGO, EN GRUPOS PARALELOS, PARA COMPARAR LA EFICACIA, LA TOLERABILIDAD Y LA SEGURIDAD DEL ACETATO DE GLATIRAMERO INYECTABLE 40 MG/ML FRENTE A ACETATO GLATIRAMERO INYECTABLE 20 MG/ML UNA VEZ AL DIA EN INYECCION SUBCUTANEA EN PACIENTES CON ESCLEROSIS MULTIPE REMITENTE RECURRENTE (EM-RR)

ESTUDIO MULTNACIONAL, MULTICENTRICO, RANDOMIZADO, DOBLE CIEGO, EN GRUPOS PARALELOS, PARA COMPARAR LA EFICACIA, LA TOLERABILIDAD Y LA SEGURIDAD DEL ACETATO DE GLATIRAMERO INYECTABLE 40 MG/ML FRENTE A ACETATO GLATIRAMERO INYECTABLE 20 MG/ML UNA VEZ AL DIA EN INYECCION SUBCUTANEA EN PACIENTES CON ESCLEROSIS MULTIPE REMITENTE RECURRENTE (EM-RR)

Datos básicos

Código:
GA/9016
Protocolo:
GA/9016
EUDRACT:
2006-002037-20
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Dotación:
Año de incio:
Año de finalización:
ENSAYO CLÍNICO

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

ALPHA BIORESEARCH S.L

Resultados del Ensayo Clínico

An algorithm to predict intrathecal synthesis of IgG with high efficiency

Tortosa-Carreres, Jordi; (...); Casanova, Bonaventura

Meeting Abstract. 2023


An expanded parenchymal CD8+ T cell clone in GABA A receptor encephalitis.

Bracher A; (...); Dornmair K

Article. 10.1002/acn3.50974. 2020


Anti-CD20 monoclonal antibodies in primary progressive multiple sclerosis: a real-life comparative study of rituximab vs. ocrelizumab

Alcala, C.; (...); Casanova, B.

Meeting Abstract. 2021


Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.

Álvarez-Sánchez L; (...); Cháfer-Pericás C

Article. 10.3390/ijms24021226. 2023


Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.

Monreal, Enric; (...); Villar LM

Article. 10.1001/jamaneurol.2023.0010. 2023


Autologous hematopoietic stem cell transplantation in multiple sclerosis: updating outcomes in the Valencian cohort.

Boix Lago, A.; (...); Casanova Estruch, B.

Meeting Abstract. 2023


Brain atrophy in relapsing optic neuritis is associated to anti-mog antibodies

Navarro Canto, L.; (...); Casanova Estruch, B.

Meeting Abstract. 2019


Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis.

Perez-Miralles, Francisco Carlos; (...); Casanova, Bonaventura

Article. 10.1002/brb3.2044. 2021


Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series.

Quintanilla-Bordás C; (...); Casanova B

Article. 10.3389/fneur.2022.897275. 2022


Cerebrospinal fluid kappa free light chains and IgM index for diagnosis and prognosis in multiple sclerosis

Gil-Perotin, S.; (...); Casanova, B.

Meeting Abstract. 2021


Cervical spinal cord T2 lesions independently predict early conversion to secondary progressive multiple sclerosis: a longitudinal 10-year study

Lacruz-Ballester, L.; (...); Casanova-Estruch, B.

Meeting Abstract. 2021


Circulating mirna signatures in PPMS

Martin, MMS; (...); Torrenta, LRI

Meeting Abstract. 2020


Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study

Oreja-Guevara, Celia; (...); Rio, Jordi

Article. 10.1016/j.msard.2024.105787. 2024


Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels

Quintanilla-Bordas, Carlos; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2024.1477335. 2024


Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.

Gil-Perotin S; (...); Casanova B

Article. 10.3389/fneur.2019.01008. 2019


Comparative Assessment of Simoa and Lumipulse for Measuring Serum Neurofilament Light Chain in Multiple Sclerosis Patients

Gasque-Rubio, Raquel; (...); Perez-Miralles, Francisco

Article. 10.1155/2024/1950913. 2024


Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis.

Medina-Polo J; (...); López-Fando L

Article. 10.1002/nau.24276. 2020


Consensus guidelines for the timely detection and diagnosis of disease progression in multiple sclerosis patients

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020


Consensus on early detection of disease progression in patients with multiple sclerosis

Meca-Lallana, Jose E.; (...); Oreja-Guevara, Celia

Article. 10.3389/fneur.2022.931014. 2022


Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA A receptor encephalitis.

Brändle SM; (...); Dornmair K

Article. 10.1073/pnas.1916337118. 2021


CSF chitinase 3-like-1 association with disability of primary progressive MS

Perez-Miralles, F; (...); Casanova, B

Article. 10.1212/NXI.0000000000000815. 2020


Changes in brain volume in specific regions could predict worsening cognition in primary progressive multiple sclerosis

Perez-Miralles, F; (...); Casanova, B

Meeting Abstract. 2019


Characterization of the gait in patients with relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis measured by FeetMe (R) integrated sensor insole system: Results of the interim analysis

Izquierdo Ayuso, G.; (...); Casanova Estruch, B.

Meeting Abstract. 2021


Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis: A one-year follow-up

Perez-Miralles, F; (...); Casanova, B

Meeting Abstract. 2019


Design and Validation of an Expanded Disability Status Scale Model in Multiple Sclerosis.

Barreiro-Gonzalez, Antonio; (...); Casanova, Bonaventura

Article. 10.1159/000519772. 2022


DISCOVER STUDY, FIRST ANALYSIS SPECIFIC FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS BURDEN AND COST IN SPAIN: INTERIM ANALYSIS RESULTS

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020


Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.

Brieva, Luis; (...); Moral, Ester

Article. 10.1016/j.msard.2022.103805. 2022


Does benign multiple sclerosis exist?

Verdini Martinez, Laura; (...); Casanova, Bonaventura

Meeting Abstract. 2023


Dynamic 18F-FDG PET to detect differences among patients with progressive and relapsing multiple sclerosis: a pilot study

Quintanilla Bordas, Carlos; (...); Casanova, Bonaventura

Meeting Abstract. 2023


Dyschromatopsia in multiple sclerosis reflects diffuse chronic neurodegeneration beyond anatomical landmarks.

Barreiro-González A; (...); Casanova B

Article. 10.1007/s13760-020-01516-x. 2020


Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers

Alvarez-Sanchez, Lourdes; (...); Chafer-Pericas, Consuelo

Article. 10.3390/ijms241814151. 2023


Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study.

Meca-Lallana, J E; (...); Calles Hernandez, C

Article. 10.1016/j.nrleng.2021.06.006. 2023


Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study

Meca-Lallana, J. E.; (...); Hernandez, C. Calles

Article. 10.1016/j.nrl.2021.06.007. 2024


Economic impact and clinical profile of the secondary progressive multiple sclerosis (SPMS) patient: the DISCOVER study

Oreja-Guevara, C.; (...); Meca-Lallana, J. E.

Meeting Abstract. 2021


Economic impact of the secondary progressive multiple sclerosis in spain: interim analysis of the discover study

Oreja-Guevara, C; (...); Meca-Lallana, J

Meeting Abstract. 2020


Eculizumab for a catastrophic relapse in NMOSD: case report.

Gorriz, David; (...); Casanova, Bonaventura

Article. 10.1007/s10072-023-06971-x. 2023


Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.

Meca-Lallana JE; (...); Llarena C

Article. 10.1007/s40120-023-00557-7. 2023


Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.

Alcala, Carmen; (...); Casanova, Bonaventura

Article. 10.1007/s00415-022-10989-0. 2022


Elevation of serum neurofilament light-chain levels disclose possible occult progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient receiving ozanimod: a case report.

Quintanilla-Bordás C; (...); Pérez-Miralles FC

Case Reports. 10.3389/fimmu.2024.1465678. 2024


Escalation vs. Early Intense Therapy in Multiple Sclerosis.

Casanova, Bonaventura, Quintanilla-Bordas, Carlos, Gascon, Francisco

Article. 10.3390/jpm12010119. 2022


Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.jneuroim.2024.578428. 2024


High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.

Castillo-Villalba, Jessica; (...); Casanova, Bonaventura

Article. 10.3389/fimmu.2022.827738. 2022


Impact of stigma in patients with primary progressive multiple sclerosis: a one-year follow-up

Perez-Miralles, F; (...); Casanova, B

Meeting Abstract. 2019


Improvements in Quality of Life of Patients with Multiple Sclerosis receiving Alemtuzumab in Clinical Practice: LEMVIDA study

Meca Lallana, Jose; (...); Forner, Mireia

Meeting Abstract. 10.1212/WNL.0000000000202381. 2023


Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.

Meca-Lallana, Jose Eustasio; (...); Toledo, Baldo

Article. 10.1186/s41687-024-00822-9. 2024


Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm.

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.msard.2023.104997. 2023


Long-term efficacy of alemtuzumab in multiple sclerosis: a real word multicenter Spanish experience

Rubio Alcantud, Almudena; (...); Casanova, Bonaventura

Meeting Abstract. 2023


Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks.

Barreiro-González A; (...); Casanova B

Article. 10.1016/j.jns.2020.117180. 2020


Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview

Garcia-Foncillas, J; (...); Gomez, MVP

Review. 10.1007/s40291-021-00544-4. 2021


miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.

Munoz-San Martin, Maria; (...); Ramio-Torrenta, Lluis

Article. 10.1212/NXI.0000000000200069. 2023


New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.

Toboso I; (...); Villar LM

Article. 10.3389/fneur.2020.579438. 2020


NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.

Alcala, C.; (...); Casanova, B.

Article. 10.1007/s00415-021-10926-7. 2022


Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis.

Alcala Vicente, Carmen; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2022.991596. 2022


Oligoclonal M bands distinguish two MS populations based on neurofilament light chain levels in patients without inflammatory activity

Castillo, J.; (...); Casanova, B.

Meeting Abstract. 2022


Oligoclonal M bands unveil occult inflammation in multiple sclerosis.

Casanova B; (...); Pérez-Miralles F

Article. 10.1016/j.msard.2022.104118. 2022


Perception of stigma in people with neuromyelitis optica spectrum disorders (PERSPECTIVES-NMO Study)

Lallana, Jose Meca; (...); Maurino, Jorge

Meeting Abstract. 2021


Peripapillary retinal nerve fibre layer correlates better with spinal cord volume than with brain parenchymal fraction in multiple sclerosis

Barreiro-Gonzalez, A; (...); Casanova, B

Meeting Abstract. 2019


Post-transplant relapse in pediatric acute lymphoblastic leukemia in the era of CAR-T cell therapy. A multicenter analysis of Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular (GETH-TC) Pediatric Committee.

Gonzalez Vicent, M; (...); Diaz de Heredia, C

Article. 10.1016/j.jcyt.2024.11.016. 2024


Potential Biomarkers Associated with Multiple Sclerosis Pathology.

Mathur, Deepali; (...); Casanova, Bonaventura

Article. 10.3390/ijms221910323. 2021


Potential Role of CHI3L1+ Astrocytes in Progression in MS.

Cubas-Núñez L; (...); Casanova B

Article. 10.1212/NXI.0000000000000972. 2021


Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.

Tortosa-Carreres J; (...); Pérez-Miralles FC

Article. 10.1016/j.msard.2024.105734. 2024


Quantifying the patient's perspective in neuromyelitis optica spectrum disorders: design of a multicenter, non-interventional study

Meca-Lallana, J; (...); Maurino, J

Meeting Abstract. 2020


Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015

Gonzalez, J; (...); Cohort Spanish HIV Res Network Co

Article. 10.1016/j.eimc.2019.02.007. 2019


Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.

Ramo-Tello, Cristina; (...); Rovira À

Article. 10.3390/jpm12010006. 2021


Renal function's impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis.

Tortosa-Carreres, Jordi; (...); Perez-Miralles, Francisco

Article. 10.1007/s10072-024-07772-6. 2024


Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.

Monreal E; (...); Villar LM

Article. 10.1093/brain/awae260. 2024


Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels at Disease Onset for Prediction of the Risk of Disability Worsening in Patients with Multiple Sclerosis

Monreal, Enric; (...); Villar Guimerans, Luisa Maria

Meeting Abstract. 2023


Serum neurofilament light chain and glial fibrillary acidic protein levels at disease onset unveil immunological pathways of disability acquisition in multiple sclerosis

Monreal, Enric; (...); Villar Guimerans, Luisa Maria

Meeting Abstract. 2024


Serum Neurofilament Light Chain is a surrogate marker of NEDA-3 in Multiple Sclerosis

Gascon Gimenez, Francisco Guillermo; (...); Casanova, Bonaventura

Meeting Abstract. 2023


Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study).

Pérez-Miralles F; (...); Casanova B

Article. 10.1016/j.msard.2021.102860. 2021


Sustained hyperammonemia induces TNF-a IN Purkinje neurons by activating the TNFR1-NF-?B pathway.

Balzano T; (...); Felipo V

Article. 10.1186/s12974-020-01746-z. 2020


Treatment of multiple sclerosis with Rituximab: a multicenter Spanish experience

Alcala, C.; (...); Casanova, B.

Meeting Abstract. 2021


Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.

Gascon-Gimenez, Francisco; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2023.1060696. 2023


Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain.

Landete, Lamberto; (...); Casanova, Bonaventura

Article. 10.3389/fneur.2021.727586. 2021


Treosulfan-Based Conditioning Regimen In Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Analysis on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).

Galán V; (...); Pérez-Martínez A

Article. 10.1016/j.jtct.2023.08.016. 2023


Campos de estudio

Compartir